Pharmaceutical filing citing Epilepsia paper — Filana Therapeutics, 2026-05-07
Filana TherapeuticsFilana TherapeuticsNASDAQ FLNA
Filings SEC · Quote Yahoo cited a paper published in Epilepsia in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S.-listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers in the document filed by Filana Therapeutics on 2026-05-07 were 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Epilepsia in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
“We believe the recent publication of preclinical data in Epilepsia and our presentation at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices further support the biological rationale behind simufilam and our approach to the potential treatment of TSC-related epilepsy.
What readers should first check is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer to that.
The scope of the paper mentioned in the abstract is limited to this.
The paper title is The small molecule simufilam dose‐dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex and it was published in Epilepsia on 2026-04-14. The authors' affiliations are Mirna Therapeutics (United States) · Yale University · TSC Alliance · Psychogenics (United States). The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was written by a person after filtering a draft generated by a machine reading the abstract, and thus it is of a different grade than a full-text reading and original judgment.
This study is an experimental investigation into the therapeutic effects of simufilam in a tuberous sclerosis complex mouse model. Mice receiving simufilam showed reduced seizure frequency and duration. The greater the drug concentration, the greater the seizure reduction effect. However, the therapeutic effect in human patients has not been confirmed.
What the abstract does not answer remains in the full text and appendices. This article, which has not gone beyond the abstract, leaves the blanks as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the company's cited passage.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −3.1% | The extent of movement before the filing |
| On the day of the filing | −4.9% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | −13.2% | One week |
| +1 to +20 trading days cumulative | −0.8% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of −0.8% in this case is within the bottom 64% of the 142 cases in the sample, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | −0.8% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies within or outside of it. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There is one more case where the same company wrote a paper in 8-K, so it is placed together in the table below.
| Disclosure date | the academic journal of the paper | one month excess return |
|---|---|---|
| 2026-07-29 | Epilepsia | +2.0% |
after the regulatory filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be identified by the number. The details of what occurred are read in the original text of each link.
- 2026-06-15 8-K Items 5.02, 5.07, 9.01 — Executive and director changes, shareholder meeting results, financial statements and attached documents
- 2026-07-29 8-K Item 2.02, 9.01 — Earnings announcement · Financial statements · Attached documents
- 2026-09-18 8-K Item 3.01 —
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper re-examined what and showed up to where. How many times the paper cited by the company has been cited afterward can be rechecked via the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.